Methods and reagents for treating glucose metabolic disorders
AssigneeCuris, Inc.
InventorsKevin Pang, Kuanghui Lu
Life of this patent
Estimating the term…
Abstract
The invention relates to methods for potentiating, enhancing or restoring glucose responsivity in pancreatic islets or cells. The methods can be used as therapies for diseases caused by, or coincident with, aberrant glucose metabolism, such as Type II Diabetes Mellitus.
Claims6
A method for promoting the growth of glucose non-responsive pancreatic cells, comprising contacting glucose non-responsive pancreatic cells with an amount of a composition comprising peptide YY (PYY) or an agonist thereof effective to promote growth of glucose non-responsive pancreatic cells, wherein the glucose non-responsive pancreatic cells include endocrine cells, and wherein said agonist is a polypeptide with at least 80% sequence identity to PYY or a fragment of PYY, and wherein the PYY or agonist thereof is a polypeptide encoded by the nucleic acid sequence that hybridizes under stringent conditions, including a wash step of 0.2×SSC at 65° C., to SEQ ID No. 1, and that binds a PYY receptor and promotes glucose responsiveness of glucose non-responsive pancreatic cells.
A method for promoting the growth of glucose non-responsive pancreatic cells, comprising contacting glucose non-responsive pancreatic cells with an amount of a composition comprising peptide YY (PYY) comprising SEQ ID No. 2 or a PYY agonist effective to promote growth of glucose non-responsive pancreatic cells, wherein the glucose non-responsive pancreatic cells include endocrine cells, and wherein said PYY agonist is a polypeptide with at least 80% sequence identity to SEQ ID No. 2 or a biologically active fragment thereof, wherein said PYY, PYY agonist, or biologically active fragment thereof binds a PYY receptor and promotes glucose-responsiveness of glucose non-responsive pancreatic cells.
Dependencies are inferred from the claim text.